Labcorp, a laboratory services provider, has announced a strategic collaboration with Hawthorne Effect to create new service offerings that support decentralised clinical trials.

Through this partnership, the companies will advance trial capabilities for biotech, pharma and medical device sponsors.

The focus will be on improving patient diversity, reducing site burden, and speeding up enrolment and study timelines.

Hawthorne Effect's digital platform facilitates complex study visits and data collection directly in patients' homes or local communities. This approach has been shown to increase patient diversity, enhance data quality and timeliness, and expedite clinical trial processes.

By combining their expertise and resources, the two companies aim to deliver improved patient experience and bring clinical trials directly to patients and investigators in local communities.

Labcorp Central Laboratories and International president Jonathan DiVincenzo said: “At Labcorp, we are committed to making life-saving clinical trials more accessible, diverse and inclusive to all communities.

“Through this collaboration, we look forward to combining Labcorp's global laboratory network and logistics capabilities with Hawthorne Effect's digital platform to advance our decentralized clinical trial capabilities, increase clinical trial accessibility and diversity, and bring greater value to patients, their physicians and our sponsors.”

Hawthorne Effect founder Jodi Akin said: “The combined expertise of both Labcorp and Hawthorne Effect will allow clinical trials to operate more efficiently with greater patient access and higher levels of compliance, resulting in timeline acceleration for customers.

“These advancements highlight our shared commitment to improving health across the globe.”

In 2022, Labcorp and non-profit organisation MD Anderson Cancer Center Foundation Spain partnered to boost access to early phase clinical trials in oncology.